Metformin, an AMPK Activator, Inhibits Radiation-Induced Skin Damage Via the FOXO3

The Future of Proton Therapy

“…As reimbursement models change and become agnostic to radiation therapy technique, there will be more effort to move this strategy into a different pathway as reimbursement for proton care will become more aligned with photon care. It will be necessary for departments to provide hybrid strategies as reimbursement becomes photon/particle transparent and internal economies of scale for patient care will need to be enhanced [25][26][27][28][29][30][31][32][33][34][35][36][37][38].…”

“…Thomas J. FitzGerald 1 *, Linda Ding 1 , Christopher Riberdy 1 , Jack Bailey 1 , Michael Anderegg 2 , Ameer Elaimy 1 , James Shen 1 *Address all correspondence to: tj.fitzgerald@umassmemorial.org with proton manufacturers remaining responsible for cost reduction to promote its application at an enterprise level [28][29][30][31][32][33][34][35][36][37][38].…”